Effects of Serum Potassium on Mortality in Patients With ST-Elevation Myocardial Infarction

Colton J Jensen1, Jonathan K Nielsen1, Matthew M Talbott1

  • 1Department of Emergency Medicine, University of Texas Medical Branch at Galveston, Galveston, USA.

Cureus
|June 26, 2024
PubMed

Insights

Potassium levels impact ST-elevation myocardial infarction (STEMI) outcomes. Both low (hypokalemia) and high (hyperkalemia) potassium significantly increase mortality and ventricular arrhythmias in STEMI patients.

Area of Science:

  • Cardiology
  • Clinical Research
  • Biomedical Science

Background:

  • Potassium disturbances are known to trigger ventricular arrhythmias and increase mortality in ST-elevation myocardial infarction (STEMI) patients.
  • Existing clinical guidelines may not fully address the risks associated with varying serum potassium (sK) levels in STEMI.

Purpose of the Study:

  • To investigate the association between serum potassium (sK) levels and seven-day mortality in STEMI patients.
  • To determine the impact of sK levels on the incidence of ventricular arrhythmias (ventricular tachycardia and ventricular fibrillation) in STEMI.

Main Methods:

  • A retrospective analysis of approximately 250,000 STEMI patients from the TriNetX database.
  • Patients were categorized into four sK cohorts: hypokalemia (≤3.4 mEq/L), normal (3.5–4.5 mEq/L), high-normal (4.6–5.0 mEq/L), and hyperkalemia (≥5.1 mEq/L).
  • Propensity-matched analysis was used to compare seven-day mortality, ventricular tachycardia (VT), and ventricular fibrillation (VF) rates across cohorts.

Main Results:

  • Hypokalemia was associated with a 69% increased risk of seven-day mortality (RR 1.69) and higher VT/VF rates compared to normal sK.
  • Hyperkalemia showed a 176% increased risk of mortality (RR 2.76) and elevated VT/VF rates.
  • High-normal sK levels were linked to a 58% increased mortality risk (RR 1.58) without a significant change in VT/VF rates.

Conclusions:

  • Serum potassium levels, including hypokalemia, hyperkalemia, and high-normal ranges, are significantly correlated with increased mortality in STEMI patients.
  • Both hypokalemia and hyperkalemia substantially elevate the risk of life-threatening ventricular arrhythmias (VT/VF).
  • The findings underscore the importance of monitoring and managing potassium levels in STEMI management to improve patient outcomes.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
136
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
511
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
965
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
Roles of Electrolytes: Sodium and Potassium01:24

Roles of Electrolytes: Sodium and Potassium

Sodium plays a crucial role in maintaining fluid and electrolyte balance and overall bodily homeostasis. Sodium balance is primarily regulated by kidney function, which adjusts sodium elimination to match dietary intake and maintain proper electrolyte levels. Sodium is the most abundant cation in the extracellular fluid (ECF) and is found in salts such as sodium chloride (NaCl) and sodium bicarbonate (NaHCO3). Although cellular plasma membranes are relatively impermeable to sodium, its role in...
350